Teladoc Health, Inc. TDOC R2K
Teladoc Health, Inc. provides virtual healthcare services worldwide. It operates through Teladoc Health Integrated Care and BetterHelp segments. The Integrated Care segment offers virtual medical services, including general medical, expert medical services, specialty medical, chronic condition management, and mental health services, as well as technologies and enterprise telehealth solutions for hospitals and health systems. Its BetterHelp segment operates a mental health platform that provides online counselling and therapy services through websites, mobile applications, phones, and text-based interactions by its licensed clinicians. The company offers its products and services under the Teladoc and BetterHelp brands. It serves employers, health plans, hospitals and health systems, insurance companies, and financial services companies, as well as individual members. The company was formerly known as Teladoc, Inc. and changed its name to Teladoc Health, Inc. in August 2018. Teladoc Health, Inc. was incorporated in 2002 and is headquartered in New York, New York.
READ MORE ›Market & Price
Valuation
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Growth (CAGR)
PROS
- Profit CAGR of 32.8% over 5 years.
- Generates positive free cash flow.
CONS
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth
No fundamental data available for this stock.
Figures from the latest reported periods. CAGR is computed across the displayed window (quarterly CAGR is annualised assuming 4 quarters per year).
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | TDOC Teladoc Health, Inc. R2K | 7.61 | - | $1.37B | - | -8.80% | -12.39% | 1.68% | 32.84% |
| 2 | LLY Eli Lilly and Company SPX | 1,105.00 | 39.21 | $985.37B | 0.63% | 38.44% | 107.46% | 31.69% | 48.96% |
| 3 | JNJ Johnson & Johnson SPX | 225.33 | 26.11 | $542.42B | 2.38% | 23.13% | 26.42% | 5.60% | 14.32% |
| 4 | UNH UnitedHealth Group Incorporated SPX | 380.31 | 28.66 | $345.38B | 2.32% | 9.60% | 12.18% | 11.35% | -15.69% |
| 5 | MRK Merck & Co., Inc. SPX | 118.72 | 33.44 | $293.22B | 2.86% | 20.66% | 18.94% | 3.12% | 7.93% |
| 6 | TMO Thermo Fisher Scientific Inc. SPX | 492.51 | 27.11 | $183.03B | 0.38% | 9.17% | 13.52% | -0.27% | -1.19% |
| 7 | AMGN Amgen Inc. NDXSPX | 336.79 | 23.42 | $181.77B | 2.99% | 18.02% | 101.32% | 11.77% | 5.58% |
| 8 | GILD Gilead Sciences, Inc. NDXSPX | 134.43 | 18.29 | $166.90B | 2.44% | 22.92% | 43.36% | 2.57% | 22.83% |
| 9 | ISRG Intuitive Surgical, Inc. NDXSPXAI | 424.64 | 51.53 | $150.39B | - | 15.96% | 17.23% | 17.39% | 29.26% |
Quarterly Results
Figures in USD.
| Metric | Sep 2014 | Mar 2015 | Jun 2015 | Sep 2015 | Mar 2016 | Jun 2016 | Sep 2016 | Dec 2016 | Mar 2017 | Jun 2017 | Sep 2017 | Dec 2017 | Mar 2018 | Jun 2018 | Sep 2018 | Dec 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 503.14M | 521.66M | 565.35M | 592.38M | 611.40M | 629.24M | 652.41M | 660.24M | 646.13M | 642.44M | 640.51M | 629.37M | 631.90M | 626.44M | 642.27M | 613.85M |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 196.83M | 190.54M | 187.18M | 197.05M | 197.53M |
| Gross Profit | 8.75M | 11.21M | 13.49M | 15.48M | 18.95M | 19.60M | 25.27M | 27.38M | 30.76M | 34.56M | 51.91M | 54.42M | 62.79M | 66.88M | 76.80M | 82.71M | 83.90M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 432.54M | 441.36M | 439.26M | 445.22M | 416.32M |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 487.48M | 487.40M | 474.72M | 472.19M | 465.05M |
| Operating Income | -3.86M | -12.59M | -16.25M | -12.60M | -14.71M | -14.46M | -20.26M | -13.23M | -14.80M | -14.49M | -21.54M | -24.56M | -19.09M | -18.15M | -15.78M | -17.84M | -22.89M | -22.02M | -19.94M | -15.59M | -21.01M | -7.18M | -19.73M | -84.68M | -78.95M | -60.58M | -6.67B | -3.10B | -71.73M | -77.10M | -71.64M | -64.72M | -87.12M | -841.15M | -44.40M | -54.94M | -46.03M | -35.46M | -26.97M | -48.73M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -15.33M | 58.94M | 46.46M | 70.55M | 38.71M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 5.76M | 4.47M | 4.53M | 4.95M | 5.37M |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -111.27M | -40.42M | -50.22M | -33.62M | -60.84M |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -18.25M | -7.76M | -715.00K | -8.47M | 3.00M |
| Net Income | -4.53M | -12.70M | -17.06M | -13.25M | -15.30M | -14.88M | -29.77M | -14.26M | -15.65M | -15.41M | -31.33M | -44.38M | -23.86M | -25.08M | -23.26M | -24.88M | -30.15M | -29.32M | -20.35M | -19.04M | -29.60M | -25.68M | -35.88M | -199.65M | -133.82M | -84.34M | -6.67B | -3.10B | -73.48M | -69.23M | -65.18M | -57.07M | -81.89M | -837.67M | -33.28M | -93.01M | -32.66M | -49.51M | -25.14M | -63.84M |
| Diluted EPS | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -1.31 | -0.86 | -0.53 | -41.58 | -19.22 | -0.45 | -0.42 | -0.40 | -0.35 | -0.49 | -4.92 | -0.19 | -15.90 | -5.70 | -8.40 | -4.20 | -10.80 |
| R&D Expense | 1.96M | 2.91M | 3.20M | 3.94M | 5.22M | 4.83M | 5.87M | 5.89M | 6.51M | 7.54M | 9.96M | 10.45M | 12.90M | 14.35M | 13.58M | 13.54M | 15.99M | 16.66M | 15.75M | 16.25M | 19.26M | 23.03M | 29.96M | 78.01M | 80.76M | 80.25M | 87.41M | 78.70M | 84.59M | 86.98M | 87.31M | 84.29M | 81.39M | 76.75M | 72.38M | 69.96M | 68.78M | 67.57M | - | 67.86M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | 1.09B | - | 2.41B | 2.60B | 2.57B | 2.53B |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | 743.99M | 760.03M | 751.27M | 771.59M |
| Gross Profit | 15.72M | 33.60M | 56.34M | 91.19M | 171.66M | 289.17M | - | - | - | 1.66B | 1.84B | 1.82B | 1.76B |
| Operating Expenses | - | - | - | - | - | - | - | - | - | 1.89B | 2.05B | 2.03B | 1.92B |
| Operating Income | -5.87M | -15.15M | -55.78M | -62.66M | -75.39M | -70.85M | -80.44M | -506.42M | - | -227.37M | -210.50M | -208.79M | -163.40M |
| EBITDA | - | - | - | - | - | - | - | - | - | -13.37B | 151.40M | -587.01M | 160.62M |
| Interest Expense | - | - | - | - | - | - | - | - | - | 21.94M | 22.28M | 23.80M | 19.71M |
| Pretax Income | - | - | - | - | - | - | - | - | - | -13.66B | -219.61M | -993.65M | -235.53M |
| Tax Provision | - | - | - | - | - | - | - | - | - | -3.81M | 760.00K | 7.59M | -35.21M |
| Net Income | -6.02M | -17.04M | -58.02M | -74.22M | -106.78M | -97.08M | -98.86M | -485.14M | - | -13.66B | -220.37M | -1.00B | -200.32M |
| Diluted EPS | - | - | - | - | - | - | -1.38 | -5.36 | - | -2,538.00 | -40.20 | -176.10 | -34.20 |
| R&D Expense | 3.53M | 7.57M | 14.21M | 21.82M | 34.46M | 54.37M | 64.64M | 164.94M | 311.88M | 333.63M | 348.52M | 307.27M | 277.92M |
Compounded Sales Growth
| 5 Years: | 1.68% |
| 1 Year: | -2.50% |
Compounded Profit Growth
| 5 Years: | 32.84% |
| 1 Year: | - |
Stock Price Performance
| 1 Year: | +9.97% |
| 6 Months: | +2.01% |
| 3 Months: | +44.68% |
| 1 Month: | +27.90% |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | - | 91.84M | 229.74M | 303.67M | 824.39M | 1.53B | 1.60B | 17.76B | - | 4.35B | 4.39B | 3.52B | 2.86B |
| Current Assets | - | - | - | - | - | - | - | - | - | - | 1.32B | 1.49B | 1.66B | 1.12B |
| Cash & Equivalents | 8.69M | 3.21M | 46.44M | 55.07M | 50.02M | 42.82M | 423.99M | 514.35M | 733.32M | - | 918.18M | 1.12B | 1.30B | 781.08M |
| Inventory | - | - | - | - | - | - | - | - | - | - | 56.34M | 29.51M | 38.14M | 38.20M |
| Receivables | - | - | - | - | - | - | - | - | - | - | 210.55M | 217.42M | 214.15M | 192.83M |
| Total Liabilities | - | - | - | - | - | - | - | - | - | - | 2.04B | 2.07B | 2.03B | 1.47B |
| Current Liabilities | - | - | 10.32M | 17.99M | 21.07M | 40.33M | 62.44M | 90.18M | 332.65M | - | 399.77M | 420.62M | 941.53M | 404.74M |
| Long Term Debt | - | - | 25.04M | 25.23M | 42.42M | - | - | - | - | - | 1.54B | 1.54B | 991.42M | 994.92M |
| Total Debt | - | - | - | - | - | - | - | - | - | - | 1.59B | 1.59B | 1.58B | 1.04B |
| Total Equity | -46.53M | -55.45M | -67.53M | 178.56M | 230.87M | 558.90M | 1.01B | 1.01B | 15.88B | - | 2.31B | 2.33B | 1.49B | 1.39B |
| Shares Outstanding | - | - | - | - | - | - | - | - | - | - | 162.84M | 166.66M | 173.41M | 178.32M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | -47.18M | -51.88M | -34.44M | -4.86M | 29.87M | -53.51M | - | 189.29M | 350.02M | 293.68M | 294.36M |
| Investing Cash Flow | - | - | -108.20M | 26.15M | -448.38M | -257.50M | 25.01M | -590.98M | - | -167.74M | -156.35M | -124.05M | -266.00M |
| Financing Cash Flow | - | - | 164.01M | 20.68M | 475.43M | 645.61M | 35.09M | 859.14M | - | 6.50M | 10.85M | 8.31M | -551.65M |
| Capital Expenditure | -204.00K | -1.07M | -6.28M | -2.11M | -2.63M | -4.01M | -3.51M | -4.02M | - | -172.76M | -156.35M | -124.05M | -157.02M |
| Free Cash Flow | - | - | -53.46M | -53.98M | -37.07M | -8.87M | 26.36M | -57.53M | - | 16.53M | 193.67M | 169.63M | 137.33M |
| Net Change in Cash | - | - | - | - | - | - | - | - | - | 28.05M | 204.53M | 177.94M | -523.30M |
| Share Buybacks | 71.00K | 368.00K | - | - | - | - | - | - | - | - | - | - | - |
Ratios (Annual)
Figures in %.
| Metric | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - | - | - | - | 69.1% | 70.8% | 70.8% | 69.5% |
| Operating Margin % | - | - | - | - | - | - | - | -46.3% | - | -9.4% | -8.1% | -8.1% | -6.5% |
| Net Margin % | - | - | - | - | - | - | - | -44.3% | - | -567.5% | -8.5% | -39.0% | -7.9% |
| ROE % | 10.9% | 25.2% | -32.5% | -32.1% | -19.1% | -9.6% | -9.7% | -3.1% | - | -591.9% | -9.5% | -67.1% | -14.5% |
| ROCE % | - | -18.6% | -26.3% | -22.2% | -9.6% | -4.8% | -5.3% | -2.9% | - | -5.8% | -5.3% | -8.1% | -6.7% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Blackrock Inc. | 8.10% | 14.61M | $111.21M |
| 2 | Vanguard Portfolio Management LLC | 6.81% | 12.30M | $93.57M |
| 3 | Renaissance Technologies, LLC | 4.48% | 8.09M | $61.53M |
| 4 | Vanguard Capital Management LLC | 4.35% | 7.86M | $59.79M |
| 5 | Point72 Asset Management, L.P. | 4.28% | 7.72M | $58.76M |
| 6 | Dimensional Fund Advisors LP | 3.49% | 6.30M | $47.93M |
| 7 | Allianz Asset Management GmbH | 2.65% | 4.79M | $36.46M |
| 8 | State Street Corporation | 2.42% | 4.36M | $33.18M |
| 9 | Voss Capital, LP | 2.33% | 4.20M | $31.96M |
| 10 | Geode Capital Management, LLC | 2.32% | 4.18M | $31.81M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for TDOC